Artiva Biotherapeutics (ARTV) Projected to Release Quarterly Earnings on Wednesday

Artiva Biotherapeutics (NASDAQ:ARTV) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.54) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). On average, analysts expect Artiva Biotherapeutics to post ($2.71) EPS for the current fiscal year and ($1.96) EPS for the next fiscal year.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $4.24 on Wednesday. Artiva Biotherapeutics has a 12-month low of $2.96 and a 12-month high of $14.53. The company has a market capitalization of $207.29 million, a PE ratio of -1.28 and a beta of 2.67. The firm’s 50-day moving average is $7.83 and its two-hundred day moving average is $7.96.

Insider Activity

In other Artiva Biotherapeutics news, insider Subhashis Banerjee sold 8,222 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $12.01, for a total transaction of $98,746.22. Following the transaction, the insider owned 142,047 shares of the company’s stock, valued at $1,705,984.47. This represents a 5.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Christopher Horan sold 10,340 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $70,725.60. Following the transaction, the insider directly owned 312,744 shares in the company, valued at approximately $2,139,168.96. This represents a 3.20% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 137,048 shares of company stock worth $1,086,167. 1.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ARTV. TD Cowen cut shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Needham & Company LLC lowered Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Jefferies Financial Group cut Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a report on Thursday, October 29th. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Monday, October 19th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Hold” and a consensus target price of $24.80.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.